Report Detail
Global CD Antigen Cancer Therapy Market Insights, Forecast to 2025
- RnM2398842 |
- 25 April, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
The global CD Antigen Cancer Therapy market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the CD Antigen Cancer Therapy market based on company, product type, end user and key regions.
This report studies the global market size of CD Antigen Cancer Therapy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of CD Antigen Cancer Therapy in these regions.
This research report categorizes the global CD Antigen Cancer Therapy market by top players/brands, region, type and end user. This report also studies the global CD Antigen Cancer Therapy market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AryoGen Biopharma
Biocad
Biogen Idec
Celltrion
Genentech
Genmab
GLYCART Biotechnology
Hetero Drugs
mAbxience
MedImmune
Merck
Sandoz
UCB
Market size by Product
Monoclonal Antibodies
Antibody-Drug-Conjugates
Tri-Functional and Bi-Specific T-Cell Engager Antibodies
Other
Market size by End User
Hospitals
Clinics
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global CD Antigen Cancer Therapy market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of CD Antigen Cancer Therapy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global CD Antigen Cancer Therapy companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of CD Antigen Cancer Therapy submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of CD Antigen Cancer Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of CD Antigen Cancer Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 CD Antigen Cancer Therapy Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Product
- 1.4.2 Monoclonal Antibodies
- 1.4.3 Antibody-Drug-Conjugates
- 1.4.4 Tri-Functional and Bi-Specific T-Cell Engager Antibodies
- 1.4.5 Other
- 1.5 Market by End User
- 1.5.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global CD Antigen Cancer Therapy Market Size
- 2.1.1 Global CD Antigen Cancer Therapy Revenue 2014-2025
- 2.1.2 Global CD Antigen Cancer Therapy Sales 2014-2025
- 2.2 CD Antigen Cancer Therapy Growth Rate by Regions
- 2.2.1 Global CD Antigen Cancer Therapy Sales by Regions
- 2.2.2 Global CD Antigen Cancer Therapy Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 CD Antigen Cancer Therapy Sales by Manufacturers
- 3.1.1 CD Antigen Cancer Therapy Sales by Manufacturers
- 3.1.2 CD Antigen Cancer Therapy Sales Market Share by Manufacturers
- 3.1.3 Global CD Antigen Cancer Therapy Market Concentration Ratio (CR5 and HHI)
- 3.2 CD Antigen Cancer Therapy Revenue by Manufacturers
- 3.2.1 CD Antigen Cancer Therapy Revenue by Manufacturers (2014-2019)
- 3.2.2 CD Antigen Cancer Therapy Revenue Share by Manufacturers (2014-2019)
- 3.3 CD Antigen Cancer Therapy Price by Manufacturers
- 3.4 CD Antigen Cancer Therapy Manufacturing Base Distribution, Product Types
- 3.4.1 CD Antigen Cancer Therapy Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers CD Antigen Cancer Therapy Product Type
- 3.4.3 Date of International Manufacturers Enter into CD Antigen Cancer Therapy Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global CD Antigen Cancer Therapy Sales by Product
- 4.2 Global CD Antigen Cancer Therapy Revenue by Product
- 4.3 CD Antigen Cancer Therapy Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global CD Antigen Cancer Therapy Breakdown Data by End User
6 North America
- 6.1 North America CD Antigen Cancer Therapy by Countries
- 6.1.1 North America CD Antigen Cancer Therapy Sales by Countries
- 6.1.2 North America CD Antigen Cancer Therapy Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America CD Antigen Cancer Therapy by Product
- 6.3 North America CD Antigen Cancer Therapy by End User
7 Europe
- 7.1 Europe CD Antigen Cancer Therapy by Countries
- 7.1.1 Europe CD Antigen Cancer Therapy Sales by Countries
- 7.1.2 Europe CD Antigen Cancer Therapy Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe CD Antigen Cancer Therapy by Product
- 7.3 Europe CD Antigen Cancer Therapy by End User
8 Asia Pacific
- 8.1 Asia Pacific CD Antigen Cancer Therapy by Countries
- 8.1.1 Asia Pacific CD Antigen Cancer Therapy Sales by Countries
- 8.1.2 Asia Pacific CD Antigen Cancer Therapy Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific CD Antigen Cancer Therapy by Product
- 8.3 Asia Pacific CD Antigen Cancer Therapy by End User
9 Central & South America
- 9.1 Central & South America CD Antigen Cancer Therapy by Countries
- 9.1.1 Central & South America CD Antigen Cancer Therapy Sales by Countries
- 9.1.2 Central & South America CD Antigen Cancer Therapy Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America CD Antigen Cancer Therapy by Product
- 9.3 Central & South America CD Antigen Cancer Therapy by End User
10 Middle East and Africa
- 10.1 Middle East and Africa CD Antigen Cancer Therapy by Countries
- 10.1.1 Middle East and Africa CD Antigen Cancer Therapy Sales by Countries
- 10.1.2 Middle East and Africa CD Antigen Cancer Therapy Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa CD Antigen Cancer Therapy by Product
- 10.3 Middle East and Africa CD Antigen Cancer Therapy by End User
11 Company Profiles
- 11.1 AryoGen Biopharma
- 11.1.1 AryoGen Biopharma Company Details
- 11.1.2 Company Business Overview
- 11.1.3 AryoGen Biopharma CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 AryoGen Biopharma CD Antigen Cancer Therapy Products Offered
- 11.1.5 AryoGen Biopharma Recent Development
- 11.2 Biocad
- 11.2.1 Biocad Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Biocad CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Biocad CD Antigen Cancer Therapy Products Offered
- 11.2.5 Biocad Recent Development
- 11.3 Biogen Idec
- 11.3.1 Biogen Idec Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Biogen Idec CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Biogen Idec CD Antigen Cancer Therapy Products Offered
- 11.3.5 Biogen Idec Recent Development
- 11.4 Celltrion
- 11.4.1 Celltrion Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Celltrion CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Celltrion CD Antigen Cancer Therapy Products Offered
- 11.4.5 Celltrion Recent Development
- 11.5 Genentech
- 11.5.1 Genentech Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Genentech CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Genentech CD Antigen Cancer Therapy Products Offered
- 11.5.5 Genentech Recent Development
- 11.6 Genmab
- 11.6.1 Genmab Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Genmab CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Genmab CD Antigen Cancer Therapy Products Offered
- 11.6.5 Genmab Recent Development
- 11.7 GLYCART Biotechnology
- 11.7.1 GLYCART Biotechnology Company Details
- 11.7.2 Company Business Overview
- 11.7.3 GLYCART Biotechnology CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 GLYCART Biotechnology CD Antigen Cancer Therapy Products Offered
- 11.7.5 GLYCART Biotechnology Recent Development
- 11.8 Hetero Drugs
- 11.8.1 Hetero Drugs Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Hetero Drugs CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Hetero Drugs CD Antigen Cancer Therapy Products Offered
- 11.8.5 Hetero Drugs Recent Development
- 11.9 mAbxience
- 11.9.1 mAbxience Company Details
- 11.9.2 Company Business Overview
- 11.9.3 mAbxience CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 mAbxience CD Antigen Cancer Therapy Products Offered
- 11.9.5 mAbxience Recent Development
- 11.10 MedImmune
- 11.10.1 MedImmune Company Details
- 11.10.2 Company Business Overview
- 11.10.3 MedImmune CD Antigen Cancer Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 MedImmune CD Antigen Cancer Therapy Products Offered
- 11.10.5 MedImmune Recent Development
- 11.11 Merck
- 11.12 Sandoz
- 11.13 UCB
12 Future Forecast
- 12.1 CD Antigen Cancer Therapy Market Forecast by Regions
- 12.1.1 Global CD Antigen Cancer Therapy Sales Forecast by Regions 2019-2025
- 12.1.2 Global CD Antigen Cancer Therapy Revenue Forecast by Regions 2019-2025
- 12.2 CD Antigen Cancer Therapy Market Forecast by Product
- 12.2.1 Global CD Antigen Cancer Therapy Sales Forecast by Product 2019-2025
- 12.2.2 Global CD Antigen Cancer Therapy Revenue Forecast by Product 2019-2025
- 12.3 CD Antigen Cancer Therapy Market Forecast by End User
- 12.4 North America CD Antigen Cancer Therapy Forecast
- 12.5 Europe CD Antigen Cancer Therapy Forecast
- 12.6 Asia Pacific CD Antigen Cancer Therapy Forecast
- 12.7 Central & South America CD Antigen Cancer Therapy Forecast
- 12.8 Middle East and Africa CD Antigen Cancer Therapy Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 CD Antigen Cancer Therapy Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on CD Antigen Cancer Therapy . Industry analysis & Market Report on CD Antigen Cancer Therapy is a syndicated market report, published as Global CD Antigen Cancer Therapy Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of CD Antigen Cancer Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
